Pharmaceuticals

FDA approves Breyanzi for relapsed or refractory mantle cell lymphoma

bexib
By bexib 0 Min Read

Breyanzi, a CD19-targeted CAR T cell therapy, has received its fourth FDA approval to treat a specific subtype of non-Hodgkin lymphoma.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article What Is Product Development? 7 Steps to Making a Product (2024)
Next Article Press buttons, turn knobs, Bleepler synth toy
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

OCBC awards S$7.5 million in financial aid to junior employees in their second year
Fintech
Large-scale inference models accelerate content marketing
Retail & E-commerce
Selfridges ringing in the new year on the roof of San Carlo’s Alto
Hospitality & Tourism
Season 2024: Exceeding expectations at Borghese Contemporary Hotel
Hospitality & Tourism